The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies - PubMed
7 hours ago
- #Gut Microbiota
- #Heart Failure
- #Pharmacological Therapies
- Heart failure (HF) involves multiorgan issues, including gut dysfunction, forming a gut-heart axis.
- Gut issues in HF like hypoperfusion and congestion lead to microbiota dysbiosis and systemic inflammation.
- New HF therapies like SGLT2 inhibitors and sacubitril/valsartan improve outcomes and may affect the gut microbiota.
- These drugs have pleiotropic effects on hemodynamics, metabolism, and inflammation, indirectly influencing gut health.
- Gut microbiota can modify drug efficacy, creating a bidirectional interaction between treatment and gut ecosystem.
- This review explores gut microbiota changes in HF and its interaction with novel therapies to personalize treatment.